Publications by authors named "Barry Cherney"

Claim this Profile
C
Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Kim Li, Gary Rogers, Yasser Nashed-Samuel, Hans Lee, Anthony Mire-Sluis, Barry Cherney

PDA J Pharm Sci Technol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
Amy S Rosenberg, Barry Cherney, Kurt Brorson, Kathleen Clouse, Steven Kozlowski

PDA J Pharm Sci Technol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of quality by design in the control of adventitious viruses: gaps in current processes in the prevention of virus contaminants.
Barry Cherney

PDA J Pharm Sci Technol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.
Amy S Rosenberg, Daniela Verthelyi, Barry W Cherney

J Pharm Sci· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific considerations for generic synthetic salmon calcitonin nasal spray products.
Sau L Lee, Lawrence X Yu, Bing Cai, Gibbes R Johnsons, Amy S Rosenberg, Barry W Cherney

AAPS J· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.
John Carpenter, Barry Cherney, Anthony Lubinecki, Stacey Ma, Ewa Marszal

Biologicals· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hurdles and leaps for protein therapeutics.
Steven Kozlowski, Barry Cherney, Raymond P Donnelly

Ann N Y Acad Sci· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.
John F Carpenter, Theodore W Randolph, Wim Jiskoot, Daan J A Crommelin, C Russell Middaugh, Barry Cherney

J Pharm Sci· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FDA's assessment of follow-on protein products: a historical perspective.
Janet Woodcock, Joseph Griffin, Rachel Behrman, Barry Cherney, Terrie Crescenzi

Nat Rev Drug Discov· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin.
Lei Yao, Sandra E Pike, Stefania Pittaluga, Barry Cherney, Ghanshyam Gupta

Cancer Immunol Immunother· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis